We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+7.88%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4B
AUM Growth
-$191M
(-4.5%)
Cap. Flow
-$236M
Cap. Flow
% of AUM
-5.9%
Top 10 Holdings %
Top 10 Hldgs %
48.84%
Holding
128
New
18
Increased
19
Reduced
24
Closed
26
Avg Time Held Equity + Options
10
quarters
Top 10 Avg Time Held Equity + Options
6.8
quarters
Top 20 Avg Time Held Equity + Options
6.6
quarters
Avg Time Held Equity only
10.6
quarters
Top 10 Avg Time Held Equity only
6.8
quarters
Top 20 Avg Time Held Equity only
6.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Caris Life Sciences
CAI
|
+$81.8M |
| 2 |
UnitedHealth
UNH
|
+$51.6M |
| 3 |
Roivant Sciences
ROIV
|
+$30.1M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$23.2M |
| 5 |
Jade Biosciences
JBIO
|
+$18.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$97.6M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$76.6M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$56.9M |
| 4 |
SpringWorks Therapeutics
SWTX
|
+$41.9M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$34.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.99% |
| 2 | Miscellaneous | 1.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
LSB
101
DELISTED
LakeShore Biopharma
LSB
| $55.9K | ﹤0.01% |
54,799
-85,629
| -61% | -$108K |
2024 Q4
2 quarters
|
|
102
Amgen
AMGN
$223B
| – | – |
-44,200
| Closed | -$13.8M | – |
|
103
Cardiff Oncology
CRDF
$78.6M
| – | – |
-573,884
| Closed | -$1.8M | – |
|
104
Fate Therapeutics
FATE
$240M
| – | – |
-1,680,580
| Closed | -$1.33M | – |
|
105
Gilead Sciences
GILD
$183B
| – | – |
-197,500
| Closed | -$22.1M | – |
|
106
CALL
Structure Therapeutics
GPCR
$1.59B
| – | – |
-150,000
| Closed | -$2.6M | – |
|
|
107
Ionis Pharmaceuticals
IONS
$7.04B
| – | – |
-2,540,136
| Closed | -$76.6M | – |
|
108
Invivyd
IVVD
$190M
| – | – |
-933,500
| Closed | -$565K | – |
|
109
Nkarta
NKTX
$150M
| – | – |
-821,400
| Closed | -$1.51M | – |
|
110
NextCure
NXTC
$28.7M
| – | – |
-95,100
| Closed | -$548K | – |
|
|
111
CALL
Pfizer
PFE
$162B
| – | – |
-500,000
| Closed | -$12.7M | – |
|
|
112
Pfizer
PFE
$162B
| – | – |
-3,850,200
| Closed | -$97.6M | – |
|
|
HLSQ
113
Tessera Defense and Homeland Security Inc.
HLSQ
$2.35M
| – | – |
-9,409
| Closed | -$993K | – |
|
114
DELISTED
ACELYRIN
SLRN
| – | – |
-4,001,711
| Closed | -$9.88M | – |
|
115
Scholar Rock
SRRK
$4.93B
| – | – |
-151,800
| Closed | -$4.88M | – |
|
|
116
CALL
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-172,600
| Closed | -$7.62M | – |
|
|
117
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-950,200
| Closed | -$41.9M | – |
|
118
Instil Bio
TIL
$41.9M
| – | – |
-116,785
| Closed | -$2.03M | – |
|
119
Tango Therapeutics
TNGX
$3.75B
| – | – |
-550,000
| Closed | -$754K | – |
|
120
Vera Therapeutics
VERA
$1.93B
| – | – |
-481,065
| Closed | -$11.6M | – |
|
121
Verastem
VSTM
$675M
| – | – |
-2,862,448
| Closed | -$17.3M | – |
|
122
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.71B
| – | – |
-100,000
| Closed | -$8.11M | – |
|
123
X4 Pharmaceuticals
XFOR
$258M
| – | – |
-225,884
| Closed | -$1.6M | – |
|
124
Xtant Medical Holdings
XTNT
$45.5M
| – | – |
-73,114,592
| Closed | -$34.4M | – |
|
125
Bicara Therapeutics
BCAX
$1.15B
| – | – |
-298,301
| Closed | -$3.89M | – |
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q2 2025 Portfolio in Review
As of Q2 2025, OrbiMed held 128 positions worth $4B, down 4.5% from $4.19B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
OrbiMed withdrew a net $236M in Q2 2025, closing 26 positions and reducing 24 holdings. Its most notable exit was Pfizer, an estimated $97.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.
Against the trend, OrbiMed opened a new position in Caris Life Sciences worth $81.1M.
- OrbiMed's largest Q2 2025 buy was Caris Life Sciences: 3,034,858 shares worth $81.1M.
- OrbiMed added most to UnitedHealth in Q2 2025, an estimated $51.6M increase.
- OrbiMed's biggest Q2 2025 reduction was Neurocrine Biosciences, cutting an estimated $56.9M.
- OrbiMed fully exited Pfizer in Q2 2025, selling an estimated $97.6M.
- OrbiMed's ten largest holdings make up 49% of its $4B portfolio in Q2 2025.
- OrbiMed opened 18 new positions and closed 26 in Q2 2025.
- OrbiMed's portfolio value fell 4.5% quarter-over-quarter to $4B.
Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.